NRSNW (NeuroSense Therapeutics) OCF Margin %: 0.00% (As of Dec. 2025)


NRSNW NeuroSense Therapeutics Ltd NRSNW
29 GF Score
Price $0.21
! 2 Warning Signs
View Full Analysis

What is NeuroSense Therapeutics OCF Margin %?

NeuroSense Therapeutics NRSNW 29 OCF Margin % is 0.00% as of Dec. 2025. GuruFocus rates NRSNW with a GF Score™ of 29/100. The stock has 2 warning signs investors should review. Among 960 Biotechnology companies, NeuroSense Therapeutics ranks worse than 104166.56% on this metric.

OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. NeuroSense Therapeutics's Cash Flow from Operations for the six months ended in Dec. 2025 was $-3.67 Mil. NeuroSense Therapeutics's Revenue for the six months ended in Dec. 2025 was $0.00 Mil. Therefore, NeuroSense Therapeutics's OCF Margin % for the quarter that ended in Dec. 2025 was 0.00%.

As of today, NeuroSense Therapeutics's current OCF Yield % is -27.29%.

The historical rank and industry rank for NeuroSense Therapeutics's OCF Margin % or its related term are showing as below:


NRSNW's OCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -68.59
* Ranked among companies with meaningful OCF Margin % only.

NeuroSense Therapeutics OCF Margin % Related Terms

NeuroSense Therapeutics OCF Margin % Historical Data

* Premium members only.

The historical data trend for NeuroSense Therapeutics's OCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NeuroSense Therapeutics OCF Margin % Chart

NeuroSense Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
OCF Margin %
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

NeuroSense Therapeutics Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
OCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
NRSNW
29GF Score
NeuroSense Therapeutics Ltd NRSNW
OCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

NeuroSense Therapeutics OCF Margin % Calculation

OCF Margin % is the ratio of Cash Flow from Operations divided by net sales or Revenue, usually presented in percent.

NeuroSense Therapeutics's OCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

OCF Margin=Cash Flow from Operations (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-7.671/0
= %

NeuroSense Therapeutics's OCF Margin for the quarter that ended in Dec. 2025 is calculated as

OCF Margin=Cash Flow from Operations (Q: Dec. 2025 )/Revenue (Q: Dec. 2025 )
=-3.671/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Margin % →
What does a OCF Margin % of 0.00% mean?
NeuroSense Therapeutics (NRSNW) has a OCF Margin % of 0.00% as of Dec. 2025. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on NeuroSense Therapeutics and its competitors. According to the industry distribution chart, NeuroSense Therapeutics ranks #999999 out of 960 companies in the Biotechnology industry.
Is NeuroSense Therapeutics' OCF Margin % too high?
NeuroSense Therapeutics' current OCF Margin % is 0.00%. Based on the distribution chart, NeuroSense Therapeutics ranks #999999 out of 960 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, NeuroSense Therapeutics has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does NeuroSense Therapeutics' OCF Margin % compare to SNTI and LSTA?
According to the Biotechnology industry distribution chart, NeuroSense Therapeutics ranks #999999 out of 960 companies for OCF Margin %. This places NeuroSense Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Biotechnology company?
A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on NeuroSense Therapeutics and its competitors. NeuroSense Therapeutics's current OCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NeuroSense Therapeutics stock overvalued right now?
NeuroSense Therapeutics (NRSNW) has a current OCF Margin % of 0.00%. The current OCF Margin % is 0.00%. NeuroSense Therapeutics' overall GF Score™ is 29/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For NeuroSense Therapeutics (NRSNW), the current OCF Margin % is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

NeuroSense Therapeutics Business Description

Other Exchanges NRSN:USAH1Z:Germany
Address 11 HaMenofim Street, Building B, Herzliya, ISR, 4672562
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.
29GF Score

Get the complete analysis for NRSNW

OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.21
Price